Uncategorized

Brigatinib first drug to offer over 1-year control of ALK-positive lung cancer post-crizotinib

Anne Li                                 5/20/17

 

About 3-5 percent of lung cancers are caused by changes in the gene ALK. In 2011, the FDA granted accelerated approval for the drug crizotinib to target these ALK changes. However, two major problems have remained: Crizotinib does not pass into the brain and so is unable to target ALK-positive lung cancer in the central nervous system, and the genetic diversity of cancer allows the later growth of subpopulations that can resist the drug, leading to renewed growth. In response, researchers have been actively developing next-generation ALK-inhibitors.

 

See original article at: https://www.sciencedaily.com/releases/2017/05/170517133018.htm

 

Comment(1)

  1. тесты зарубежная азия 11 класс география says

    I have read so many articles regarding the blogger lovers but this post is truly a nice post, keep it up.| а

Post a comment